A. TOMBAK Et Al. , "Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study," ASH , vol.134, United States Of America, pp.5476, 2019
TOMBAK, A. Et Al. 2019. Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study. ASH , (United States Of America), 5476.
TOMBAK, A., FUNDA, P., DURUSOY, S. S., GÜRKAN, E., KAYA, E., ÜMİT, E. G., ... YAVAŞOĞLU, İ.(2019). Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study . ASH (pp.5476). , United States Of America
TOMBAK, ANIL Et Al. "Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study," ASH, United States Of America, 2019
TOMBAK, ANIL Et Al. "Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study." ASH , United States Of America, pp.5476, 2019
TOMBAK, A. Et Al. (2019) . "Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study." ASH , United States Of America, p.5476.
@conferencepaper{conferencepaper, author={ANIL TOMBAK Et Al. }, title={Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study}, congress name={ASH}, city={}, country={United States Of America}, year={2019}, pages={5476} }